Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[High altitude pulmonary edema]

N Tokimitsu1, Y Okano, M Nishio

  • 1Department of Internal Medicine, Takayama Red Cross Hospital.

Ryoikibetsu Shokogun Shirizu
|February 1, 1994
PubMed
Summary

No abstract available in PubMed .

Related Experiment Videos

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Association between skin toxicity and efficacy of necitumumab in squamous non-small-cell lung cancer: a pooled analysis of two randomized clinical trials-SQUIRE and JFCM.

ESMO open·2024
Same author

Translational insights and overall survival in the U31402-A-U102 study of patritumab deruxtecan (HER3-DXd) in EGFR-mutated NSCLC.

Annals of oncology : official journal of the European Society for Medical Oncology·2024
Same author

Ramucirumab plus erlotinib versus placebo plus erlotinib in previously untreated EGFR-mutated metastatic non-small-cell lung cancer (RELAY): exploratory analysis of next-generation sequencing results.

ESMO open·2023
Same author

Long-term survival with first-line nivolumab plus ipilimumab in patients with advanced non-small-cell lung cancer: a pooled analysis.

Annals of oncology : official journal of the European Society for Medical Oncology·2022
Same author

Final overall survival analysis from the phase III J-ALEX study of alectinib versus crizotinib in ALK inhibitor-naïve Japanese patients with ALK-positive non-small-cell lung cancer.

ESMO open·2022
Same author

First-line nivolumab + ipilimumab in advanced NSCLC: CheckMate 227 subpopulation analyses in Asian patients.

ESMO open·2022
Same journal

[Substance-related mental disorders and expert testimony].

Ryoikibetsu shokogun shirizu·2003
Same journal

[Nicotine-related mental disorders].

Ryoikibetsu shokogun shirizu·2003
Same journal

[Organic solvent-related mental disorders].

Ryoikibetsu shokogun shirizu·2003
Same journal

[Hallucinogen related mental disorder].

Ryoikibetsu shokogun shirizu·2003
Same journal

[Methylphenidate-induced psychiatric disorders].

Ryoikibetsu shokogun shirizu·2003
Same journal

[Sensitization phenomenon].

Ryoikibetsu shokogun shirizu·2003
See all related articles